5-Fluorouracil is an antimetabolite fluoropyrimidine used in oncology. It is metabolized to active nucleotide analogs that inhibit thymidylate synthase and interfere with RNA and DNA synthesis, producing cytotoxic effects in rapidly dividing cells.
A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
The U.S. FDA granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro as monotherapy for adults with advanced head and neck squamous cell carcinoma, based on Phase 1b/2 study data showing rapid and durable responses.
The FDA has approved a monthly dosing schedule for Rybrevant Faspro in EGFR-mutated NSCLC and granted breakthrough therapy designation for the drug as monotherapy in HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
The FDA approved a once-monthly dosing schedule for Rybrevant Faspro with Lazcluze for first-line treatment of EGFR-mutated advanced NSCLC, reducing clinic visits while maintaining safety and efficacy established with bi-weekly dosing.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07554456 |
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07441369 |
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT07431281 |
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 |
RECRUITING | PHASE3 |
| NCT07419464 |
5-Fluorouracil Response and Optimization STudy (The FROST Trial) |
RECRUITING | PHASE2 |
| NCT07352566 |
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07150247 |
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer |
RECRUITING | PHASE2 |
| NCT07096362 |
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma |
RECRUITING | PHASE2 |
| NCT07076212 |
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma |
RECRUITING | PHASE2 |
| NCT07070466 |
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA |
RECRUITING | PHASE2 |
| NCT07028424 |
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment |
NOT_YET_RECRUITING | PHASE2 |
